USA flag logo/image

An Official Website of the United States Government

Novel Therapeutic for Amyotrophic Lateral Sclerosis (ALS)

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
89426
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
NS063483
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ANGION BIOMEDICA CORPORATION
51 Charles Lindbergh Blvd Uniondale, NY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Novel Therapeutic for Amyotrophic Lateral Sclerosis (ALS)
Agency: HHS
Contract: 1R43NS063483-01
Award Amount: $184,012.00
 

Abstract:

DESCRIPTION (provided by applicant): Literature indicates that HGF via its cytoprotective and tissue-regenerative activities protects a number of organs against traumatic and/or ischemic injury and fibrotic/degenerative disease. We have evaluated the effec ts of BB3/Rf in preclinical models of ischemic stroke, hepatic, renal, pulmonary and myocardial ischemia-reperfusion injury including models of hepatic, renal and lung transplantation. Treatment with BB3/Rf was associated with reduced mortality, improved o rgan function and preservation of tissue microarchitecture. These efficacy data (not presented here) and the efficacy of BB3/Rf to attenuate spinal cord injury as described in the preliminary results section, coupled with an excellent safety profile and id eal drug ability characteristic makes BB3/RF an ideal candidate for evaluation in other indications where HGF has shown efficacy, such as ALS. We are in the unique position to test out small molecular weight HGF mimetic in the setting of ALS, where various nueorotrophic factors have failed in the clinic, likely due in part to the extreme difficulty of adequately delivering such macromolecular, polypeptides, which will not cross the blood-brain barrier, to the CNS. BB3/RF will not have such limitations. PUBL IC HEALTH RELEVANCE: Recently HGF has demonstrated excellent efficacy in a mouse model of ALS. In this proposal, we are poised to determine if our small molecule, HGF mimetic BB3/Rf will prove similarly efficacious. If so, further studies could bring BB3/R F to the clinic as a possible therapy for ALS, a devastating disease with significant unmet medical need.

Principal Investigator:

Business Contact:


igoldberg@angion.com
Small Business Information at Submission:

ANGION BIOMEDICA CORPORATION
ANGION BIOMEDICA CORP 1050 Stewart Ave. Garden City, NY 11530

EIN/Tax ID: 113430072
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No